Overview

Flexible-Dose Trial in Early Parkinson's Disease (PD)

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Cerevel Therapeutics, LLC
Criteria
Key Inclusion Criteria:

- Male and female participants aged 40 to 80 years, inclusive, at the time of signing
the informed consent form (ICF).

- Sexually active men or women of childbearing potential must agree to use acceptable
(at minimum) or highly effective birth control, or remain abstinent during the trial
and for 4 weeks after the last dose of trial treatment.

- Participants who are capable of giving signed informed consent, which includes
compliance with the requirements and restrictions listed in the ICF and in the
protocol.

- Participants with a diagnosis of PD that is consistent with the UK Parkinson's Disease
Society Brain Bank diagnostic criteria, with bradykinesia and motor asymmetry.

- Participants with modified Hoehn and Yahr stage 1, 1.5, or 2.

- Participants with disease duration (from time of diagnosis) of less than (<) 3 years
and disease progression in the 3 years before signing the ICF.

- Participants with an MDS-UPDRS Part II score >=2 and Part III score >=10 at the
Screening Visit.

- Participants with early PD who, in the opinion of the investigator, require
pharmacologic intervention for disease management.

- Participants who are treatment naïve or have a history of prior incidental treatment
with dopaminergic agents (including Levodopa [L-Dopa] and dopamine receptor agonist
medications) for <3 months in total but not within 2 months of signing the ICF. Prior
and concurrent use of Monoamine oxidase B (MAO-B) inhibitors is permitted if use was
initiated greater than (>) 90 days before signing of the ICF and the dosage will
remain stable for the duration of the trial (no change in the MAO-B inhibitor dose is
permitted during the trial).

- Participants who are willing and able to refrain from any PD medications that are not
permitted by the protocol (including dopaminergic agents) throughout participation in
the trial.

Key Exclusion Criteria:

- Participants with a history or clinical features consistent with essential tremor,
atypical or secondary parkinsonian syndrome (including, but not limited to,
progressive supra nuclear palsy, multiple system atrophy, cortico-basal degeneration,
or drug-induced or post stroke parkinsonism).

- Participants with a history of nonresponse or insufficient response to L-Dopa at
therapeutic dosages.

- Participants with a history or current diagnosis of a clinically significant impulse
control disorder (Disruptive, Impulse Control, and Conduct Disorder per DSM-5).

- Participants with the presence of or history of brain tumor, hospitalization for
severe head trauma, epilepsy (as defined by the International League Against
Epilepsy), or seizures.

- Participants with a history of psychosis or hallucinations within the previous 12
months.

- Participants who answer "yes" on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active
Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal
Ideation with Specific Plan and Intent) and whose most recent episode meeting the
criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR
Participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual
attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and
whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal
Behavior Items occurred within the last 2 years, OR Participants who, in the opinion
of the investigator, present a serious risk of suicide.

- Participants with substance abuse or dependence disorder, including alcohol,
benzodiazepines, and opioids, but excluding nicotine, within the past 6 months (180
days).

- Participants with dementia or cognitive impairment that, in the judgement of the
investigator, would exclude the participant from understanding the ICF or
participating in the trial.

- Participants with any condition that could possibly affect drug absorption, including
bowel resections, bariatric weight loss surgery, or gastrectomy (this does not include
gastric banding).

- Participants who have a positive result for human immunodeficiency virus (HIV)
antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) antibodies
at screening.

- Participants with a history of myocardial infarction with residual atrial, nodal, or
ventricular arrhythmias that are not controlled with medical and/or surgical
intervention; second- or third-degree atrioventricular block; sick sinus syndrome;
severe or unstable angina; or congestive heart failure within the last 12 months. A
recent (less than or equal to [<=] 12 months) history of myocardial infarction with
secondary arrhythmias is exclusionary regardless of the therapeutic control.

- Participants with a history of neuroleptic malignant syndrome.

- Participants who are currently receiving moderate or strong CYP3A4 inducers or CYP3A4
inhibitors (except for topical administration).

- Participants with a positive urine drug screen for illicit drugs are excluded and may
not be retested or rescreened. Participants with a positive urine drug screen
resulting from use of marijuana (any Tetrahydrocannabinol [THC]-containing product),
prescription, or over-the-counter medications or products that, in the investigator's
documented opinion, do not signal a clinical condition that would impact the safety of
the participant or interpretation of the trial results may continue evaluation for the
trial following consultation and approval by the medical monitor.

- Participants with a Montreal Cognitive Assessment (MoCA) score <26.

- Participants with clinically significant orthostatic hypotension (eg, syncope).

- Participants with a 12-lead ECG demonstrating a QTcF interval >450 msec.

- Participants with moderate or severe renal impairment (creatinine clearance as
estimated by Cockcroft-Gault formula <30 mL/min or on dialysis).

- Participants with any of the following abnormalities in clinical laboratory tests at
the Screening Visit, as assessed by the central laboratory and confirmed by a single
repeat measurement, if deemed necessary:

- Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) >=3 × Upper
Limit Normal (ULN).

- Total bilirubin >=1.5 × ULN. Participants with a history of Gilbert's syndrome
may be eligible provided they have a value
- Participants with other abnormal laboratory test results, vital sign results, or ECG
findings unless, in the judgment of the investigator, the findings are not medically
significant and would not impact the safety of the participants or the interpretation
of the trial results.